MK3475-B61 - A Phase 2, Single-arm, Open-label Clinical Trial of Pembrolizumab Plus Lenvatinib in Participants with First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (nccRCC) (KEYNOTE-B61)
- Gurney, Howard (Primary Chief Investigator)
- Chapman, Nicola (Clinical Trial Unit Staff)
- Tan, Pearlyn (Clinical Trial Unit Staff)
Project: Research